Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

1005 - Comparision of irinotecan/cisplatin with etoposide/cisplatin in North-West Indian population with extensive-stage disease small-cell lung cancer

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

Surender Beniwal

Citation

Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532

Authors

S.K. Beniwal1, S. Narayan2, G.S. Rao2, M.K. Singhal2, S.L. Jakher2, S.R. Maheria2, N. Sharma2, H.S. Kumar2, A. Sharma2

Author affiliations

  • 1 Medical Oncology, Acharya Tulsi Regional Cancer Treatment & Research Institute, 334001 - Bikaner/IN
  • 2 Radiation Oncology, Acharya Tulsi Cancer Treatment & Research Institut, 334001 - Bikaner/IN
More

Resources

Abstract 1005

Aim/Background

Etoposide and Cisplatin (EP) has been a recognized treatment option for extensive stage disease small-cell lung cancer. The principal of study to determine the effect of Irinotecan/Cisplatin with Etoposide/Cisplatin in North-west Indian population with formerly untreated extensive-stage disease small-cell lung cancer (ES-SCLC).Etoposide and Cisplatin (EP) has been a recognized treatment option for extensive stage disease small-cell lung cancer. The principal of study to determine the effect of Irinotecan/Cisplatin with Etoposide/Cisplatin in North-west Indian population with formerly untreated extensive-stage disease small-cell lung cancer (ES-SCLC).

Methods

The primary objective was to compare survival in ES-SCLC patients, randomly enrolled to receive IP (n = 59) or EP (n = 61). Patients have received Cisplatin 60 mg/m2 intravenously (IV) on day 1 and Irinotecan 65 mg/m2 IV on days 1 and 8 every 21 days, versus Cisplatin 80 mg/m2 IV on day 1,2 in divided doses and Etoposide 120 mg/m2 IV on day 1 to 3 every 21 days for at least six cycles. Patients with non progressive disease after first-line treatment were considered for prophylactic cranial irradiation. All statistical calculations were performed using SPSS version 20.0 software.

Results

The median disease free survival for IP/EP was 5.1 (95% CI: 4.3-6.9) versus 4.8 months (95% CI: 4.0-6.7) (P= 0.92) and median overall survival 9.7 months (95% CI: 8.8-10.6) v 10.6 months (95% CI: 9.1-11.2) P = 0.84). The patients treated with PCI for IP/EP were (35.6% v 32.8%; P = 0.73). The grade 3/4 toxicities were for IP/EP: neutropenia (37.3% v 78.7%; P <.01), febrile neutropenia (5.1% v 11.4%; P =.12), anemia (6.7% v 16.4%; P = .04), thrombocytopenia (5.1% v 18.0%; P < .01), diarrhea (22.0% v 1.6%; P < .01) and vomiting (10.2% v 4.9%; P = .17).

Conclusions

Treatment with IP was non inferior when compared with EP in North-west Indian population, while comparing the survival analysis (DFS and OS). But patients receiving IP had less grade 3/4 neutropenia, febrile neutropenia, anemia and thrombocytopenia compared with patients receiving EP, but had more diarrhea and vomiting.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings